Skip to content


Clinical Trials Monitor

Section edited by Leisha A. Emens, MD, PhD

Reports on important new trial results; updates on new drug approvals and ongoing clinical studies; key perspectives on clinical issues and advances in the field relevant to the everyday use of cancer immunotherapy in the clinic. This section also aims to address trial design and analysis considerations that may be unique to cancer immunotherapy, and to provide guidance for implementing and managing the use of cancer immunotherapies in the clinic.

  1. Content type: Review article

    Immune checkpoint antagonists (CTLA-4 and PD-1/PD-L1) and CAR T-cell therapies generate unparalleled durable responses in several cancers and have firmly established immunotherapy as a new pillar of cancer the...

    Authors: Robert D. Leone and Leisha A. Emens

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:57

    Published on:

  2. Content type: Review article

    The U.S. Food and Drug Administration (FDA) recently approved pembrolizumab, an anti- programmed cell death protein 1 cancer immunotherapeutic, for use in advanced solid tumors in patients with the microsatell...

    Authors: Michael M. Boyiadzis, John M. Kirkwood, John L. Marshall, Colin C. Pritchard, Nilofer S. Azad and James L. Gulley

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:35

    Published on:

  3. Content type: Research article

    Merkel Cell carcinoma (MCC) is a rare but aggressive cancer, with an estimated disease-associated mortality as high as 46%. MCC has proven to be an immunologically responsive disease and the advent of immune c...

    Authors: Isaac S. Chan, Shailender Bhatia, Howard L. Kaufman and Evan J. Lipson

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:23

    Published on:

  4. Content type: Review

    Early preclinical evidence provided the rationale for programmed cell death 1 (PD-1) and programmed death ligand 1 (PD-L1) blockade as a potential form of cancer immunotherapy given that activation of the PD-1...

    Authors: Jun Gong, Alexander Chehrazi-Raffle, Srikanth Reddi and Ravi Salgia

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:8

    Published on:

  5. Content type: Clinical trials monitor

    Increasing evidence demonstrates that radiation acts as an immune stimulus, recruiting immune mediators that enable anti-tumor responses within and outside the radiation field. There has been a rapid expansion...

    Authors: Josephine Kang, Sandra Demaria and Silvia Formenti

    Citation: Journal for ImmunoTherapy of Cancer 2016 4:51

    Published on:

  6. Content type: Clinical trials monitor

    With the recent regulatory approval of Talimogene laherparepvec (T-VEC) for the treatment of advanced of melanoma in the United States, Europe and Australia, oncolytic virus immunotherapy has earned its place ...

    Authors: Hasan Rehman, Ann W. Silk, Michael P. Kane and Howard L. Kaufman

    Citation: Journal for ImmunoTherapy of Cancer 2016 4:53

    Published on:

  7. Content type: Clinical trials monitor

    Because the benefits of immune checkpoint blockade may be restricted to tumors with pre-existing immune recognition, novel therapies that facilitate de novo immune activation are needed. DRibbles is a novel multi...

    Authors: David B. Page, Tyler W. Hulett, Traci L. Hilton, Hong-Ming Hu, Walter J. Urba and Bernard A. Fox

    Citation: Journal for ImmunoTherapy of Cancer 2016 4:25

    Published on:

2017 Journal Metrics